GlassScriptPhysician profile
Jaafar Al-Dahwi
NPI 1639551435
$7,481.63
in general payments reported to CMS, 2019-2025
51 companies · $2,100 in 2025
The $2,100 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $231 · 2022: $1,536 · 2023: $1,588 · 2024: $2,026 · 2025: $2,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,714.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $924.19 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $899.17 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $658.29 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $567.74 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $469.38 | 2021-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $461.53 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $353.69 | 2021-2025 | |
| Pfizer INC. | $281.66 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $268.84 | 2022-2025 | |
| Madrigal Pharmaceuticals | $244.97 | 2024-2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.56 | 2023-2025 | Xifaxan, Trulance |
| Boston Scientific Corporation | $182.63 | 2021-2024 | Watchman Access System |
| Sanofi Pasteur INC. | $182.17 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $134.21 | 2024-2025 | Rexulti |
| Hologic Sales and Service, LLC | $99.14 | 2023-2025 | Aptima, Thinprep 2000 Processor |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $95.91 | 2022-2024 | Ingrezza |
| Halozyme INC | $95.18 | 2023 | |
| Exact Sciences Corporation | $94.53 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $88.91 | 2024-2025 | Veozah |
| Abbott Laboratories | $88.58 | 2022-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $88.48 | 2022-2025 | |
| Baxter Healthcare | $85.45 | 2022-2025 | Hillrom - Volara System, Hillrom - Cardiac Ambulatory Monitor |
| Gilead Sciences, INC. | $79.54 | 2023-2025 | |
| Daiichi Sankyo INC. | $71.99 | 2024 | Injectafer |
| Viiv Healthcare Company | $68.54 | 2025 | Apretude |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.01 | 2021-2022 | |
| Atricure, INC. | $59.33 | 2024 | |
| Antares Pharma, INC. | $57.91 | 2023-2024 | Xyosted, Tlando, Nocdurna |
| Averitas Pharma INC. | $42.96 | 2025 | Qutenza |
| Seqirus USA INC | $32.75 | 2025 | Flucelvax, Fluad |
| Medtronic, INC. | $30.33 | 2024 | Intellis Adaptivestim |
| Biohaven Pharmaceuticals, INC. | $29.58 | 2021 | |
| Corium, LLC | $29.17 | 2024 | Azstarys |
| Actelion Pharmaceuticals US, INC. | $27.10 | 2023 | Uptravi, Opsumit |
| Scpharmaceuticals INC. | $26.29 | 2025 | |
| Microtransponder, INC. | $26.28 | 2025 | |
| Genzyme Corporation | $25.62 | 2025 | |
| Irhythm Technologies, INC. | $24.63 | 2024 | Zio Xt Patch, Zio Monitor |
| Alnylam Pharmaceuticals INC. | $24.09 | 2024 | Amvuttra |
| Kyowa Kirin, INC. | $22.26 | 2025 | |
| Phathom Pharmaceuticals, INC. | $20.19 | 2024 | Voquezna |
| Tactile Systems Technology INC | $20.12 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.99 | 2022 | |
| Abiomed | $17.40 | 2025 | |
| Eisai INC. | $17.28 | 2022 | |
| Therapeuticsmd, INC. | $16.69 | 2022 | |
| Merck Sharp & Dohme LLC | $14.34 | 2021 | |
| Genentech USA, INC. | $14.06 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.92 | 2022 | |
| Si-Bone, INC. | $12.25 | 2021 | |
| Cequr Corporation | $9.80 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaafar Al-Dahwi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.